Escitalopram
Major Depressive Disorder
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Shanghai 7th People's Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07645807CT.gov Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram. | — | Not Yet Recruiting | — | — | — |
NCT06705478CT.gov Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV | — | Recruiting | — | — | — |
NCT07139834CT.gov Pattern Separation in Major Depressive Disorder | — | Not Yet Recruiting | — | — | — |
NCT07480525CT.gov Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder | — | Not Yet Recruiting | — | — | — |
NCT07488910CT.gov Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression | — | Not Yet Recruiting | — | — | — |
NCT07458022CT.gov MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER | — | Active Not Recruiting | — | — | — |
NCT07011693CT.gov Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I) | — | Not Yet Recruiting | — | — | — |
NCT06937476CT.gov Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole | — | Active Not Recruiting | — | — | — |
NCT05603104CT.gov Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | — | Recruiting | — | — | — |
NCT06965569CT.gov Multiple Ascending Dose Phase 1 Study of ALA-3000 | — | Completed | — | — | — |
Show 154 more trialsShow fewer
NCT07478796CT.gov TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | — | Recruiting | — | — | — |
NCT06828887CT.gov Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD | — | Recruiting | — | — | — |
NCT06692361CT.gov Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder | — | Recruiting | — | — | — |
NCT05932407CT.gov A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression | — | Completed | — | — | — |
NCT06476509CT.gov A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET | — | Completed | — | — | — |
NCT05554627CT.gov VA Aripiprazole vs Esketamine for Treatment Resistant Depression | — | Withdrawn | — | — | — |
NCT07590609CT.gov Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression. | — | Completed | — | — | — |
NCT05017311CT.gov Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D) | — | Recruiting | — | — | — |
NCT06675851CT.gov Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People | — | Recruiting | — | — | — |
NCT05536414CT.gov Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT06054321CT.gov Psychopharmacotherapy for Depressive Patients | — | Recruiting | — | — | — |
NCT04446039CT.gov Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea | — | Completed | — | — | — |
NCT05950061CT.gov Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder | — | Completed | — | — | — |
NCT05480150CT.gov Chinese Longitudinal and Systematic Study of Bioplar Disorder | — | Recruiting | — | — | — |
NCT04697693CT.gov Antidepressant Response in Older Adults With Comorbid PTSD and MDD | — | Terminated | — | — | — |
NCT06758167CT.gov RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD | — | Completed | — | — | — |
NCT04476030CT.gov A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT04388202CT.gov Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram | — | Withdrawn | — | — | — |
NCT04531423CT.gov PKC as Serum Biomarkers for Depression | — | Unknown | — | — | — |
NCT05210140CT.gov Personalized Escitalopram Dosing in Patients With Depression | — | Unknown | — | — | — |
NCT04156425CT.gov The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression | — | Unknown | — | — | — |
NCT04410341CT.gov The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients | — | Withdrawn | — | — | — |
NCT07077291CT.gov MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults | — | Completed | — | — | — |
NCT04162522CT.gov Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study | — | Completed | — | — | — |
NCT05145270CT.gov A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment | — | Unknown | — | — | — |
NCT04069819CT.gov The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. | — | Completed | — | — | — |
NCT04037111CT.gov Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms | — | Unknown | — | — | — |
NCT03779789CT.gov Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment | — | Completed | — | — | — |
NCT03812588CT.gov Contact: Developing New Clinical Management Strategies | — | Completed | — | — | — |
NCT03429075CT.gov Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms | — | Completed | — | — | — |
NCT03899194CT.gov Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder | — | Unknown | — | — | — |
NCT03790085CT.gov Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals | — | Unknown | — | — | — |
NCT03623711CT.gov A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression | — | Unknown | — | — | — |
NCT04543123CT.gov Effect of Self-administered tDCS in Patients With MDD | — | Completed | — | — | — |
NCT03128021CT.gov Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO) | — | Completed | — | — | — |
NCT02977299CT.gov Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD | — | Completed | — | — | — |
NCT03122158CT.gov Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders | — | Unknown | — | — | — |
NCT03131050CT.gov Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD | — | Completed | — | — | — |
NCT02752542CT.gov Personalized Indications for CBT and Antidepressants in Treating Depression | — | Recruiting | — | — | — |
NCT03187093CT.gov Cognitive Dysfunction in MDD Patients | — | Unknown | — | — | — |
NCT02674529CT.gov Study of Neural Responses Induced by Antidepressant Effects | — | Completed | — | — | — |
NCT02869035CT.gov Treatment Outcome in Major Depressive Disorder | — | Completed | — | — | — |
NCT04013464CT.gov Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT02497287CT.gov A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | — | Completed | — | — | — |
NCT02417064CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02418585CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02711215CT.gov Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR) | — | Unknown | — | — | — |
NCT03554447CT.gov Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT02332291CT.gov Connectivity Affecting the Antidepressant REsponse Study | — | Completed | — | — | — |
NCT01870843CT.gov A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom | — | Completed | — | — | — |
NCT01931202CT.gov Mechanisms of Antidepressant Non-Response in Late-Life Depression | — | Completed | — | — | — |
NCT01483053CT.gov Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) | — | Unknown | — | — | — |
NCT01942187CT.gov A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults | — | Withdrawn | — | — | — |
NCT01997580CT.gov Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder | — | Unknown | — | — | — |
NCT01896349CT.gov Interpersonal Psychotherapy for Treatment Resistant Depression | — | Unknown | — | — | — |
NCT01787240CT.gov Neurobiological Bases of Placebo Response in Major Depressive Disorder | — | Terminated | — | — | — |
NCT02082392CT.gov Developing New Clinical Management Strategies | — | Completed | — | — | — |
NCT01764867CT.gov Algorithm Guided Treatment Strategies for Major Depressive Disorder | — | Unknown | — | — | — |
NCT01594866CT.gov Lexapro®'s Efficacy After Dose Escalation in Remission Study | — | Completed | — | — | — |
NCT01655706CT.gov Canadian Biomarker Integration Network for Depression Study | — | Completed | — | — | — |
NCT01741142CT.gov Efficacy and Safety Study of ABT-436 in Major Depressive Disorder | — | Terminated | — | — | — |
NCT01488266CT.gov Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder | — | Unknown | — | — | — |
NCT01477203CT.gov Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders | — | Completed | — | — | — |
NCT01436162CT.gov Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01360866CT.gov Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | — | Completed | — | — | — |
NCT02237937CT.gov Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene | — | Unknown | — | — | — |
NCT01429831CT.gov Aripiprazole for the Augmentation of Antidepressant Therapy | — | Completed | — | — | — |
NCT01424111CT.gov Exploring Biomarkers for Depression | — | Completed | — | — | — |
NCT01370499CT.gov A Study of LY2216684 in Participants With Major Depression Disorder | — | Completed | — | — | — |
NCT01435759CT.gov SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01299272CT.gov A Study in Prevention of Re-emergence of Depression Symptoms | — | Completed | — | — | — |
NCT01185340CT.gov A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor | — | Completed | — | — | — |
NCT01309776CT.gov Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder | — | Completed | — | — | — |
NCT01187407CT.gov A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment | — | Completed | — | — | — |
NCT01123707CT.gov To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01173601CT.gov A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01111565CT.gov Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01155661CT.gov A Safety Study in Participants With Major Depressive Disorder | — | Completed | — | — | — |
NCT01219686CT.gov EScitalopram PIndolol ONset of Action | — | Terminated | — | — | — |
NCT01363310CT.gov The Quietude Study: Quetiapine Use for Agitated Depression | — | Terminated | — | — | — |
NCT01198795CT.gov Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder | — | Completed | — | — | — |
NCT01111552CT.gov Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01111539CT.gov Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT02480400CT.gov The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression | — | Completed | — | — | — |
NCT01368432CT.gov Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions | — | Completed | — | — | — |
NCT01034995CT.gov A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder | — | Completed | — | — | — |
NCT01814085CT.gov A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression | — | Completed | — | — | — |
NCT01020799CT.gov AZD7268 Safety and Tolerability Study | — | Completed | — | — | — |
NCT01082237CT.gov Biomarkers for Outcomes In Late-life Depression (BOLD) | — | Completed | — | — | — |
NCT01369290CT.gov Electroencephalography (EEG) Signal Processing | — | Unknown | — | — | — |
NCT00660062CT.gov Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7) | — | Terminated | — | — | — |
NCT00905424CT.gov Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant | — | Completed | — | — | — |
NCT01814098CT.gov An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms | — | Completed | — | — | — |
NCT00965497CT.gov Escitalopram (Lexapro) for Depression MS or ALS | — | Completed | — | — | — |
NCT00854100CT.gov Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder | — | Completed | — | — | — |
NCT00953745CT.gov Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression | — | Completed | — | — | — |
NCT01541475CT.gov Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00822744CT.gov An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients | — | Completed | — | — | — |
NCT00807248CT.gov Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder | — | Completed | — | — | — |
NCT00810069CT.gov Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00785434CT.gov Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD | — | Completed | — | — | — |
NCT00693849CT.gov International Study to Predict Optimised Treatment - in Depression | — | Unknown | — | — | — |
NCT00824044CT.gov Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression | — | Completed | — | — | — |
NCT00628914CT.gov Brain Mechanisms and Targeting Insomnia in Major Depression | — | Unknown | — | — | — |
NCT00707863CT.gov Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram | — | Completed | — | — | — |
NCT00668525CT.gov Escitalopram in Adult Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00650897CT.gov Efficacy Study of Escitalopram for Depression in Patients With Diabetes | — | Unknown | — | — | — |
NCT00620789CT.gov Behavioral Insomnia Therapy For Those With Insomnia and Depression | — | Unknown | — | — | — |
NCT00621946CT.gov Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder | — | Completed | — | — | — |
NCT00590863CT.gov Combining Medications to Enhance Depression Outcomes | — | Completed | — | — | — |
NCT00566202CT.gov A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression | — | Completed | — | — | — |
NCT00531622CT.gov An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder | — | Completed | — | — | — |
NCT00519428CT.gov Does Dual Therapy Hasten Antidepressant Response? | — | Completed | — | — | — |
NCT00642694CT.gov Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon | — | Terminated | — | — | — |
NCT00474708CT.gov Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients | — | Completed | — | — | — |
NCT00452543CT.gov Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism | — | Completed | — | — | — |
NCT00343070CT.gov Functional Neuroimaging in Depression | — | Completed | — | — | — |
NCT00442481CT.gov Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder | — | Unknown | — | — | — |
NCT03927950CT.gov Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment | — | Completed | — | — | — |
NCT00432614CT.gov Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT00406640CT.gov Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women | — | Completed | — | — | — |
NCT00420004CT.gov A Study for Participants With Major Depression | — | Completed | — | — | — |
NCT00595699CT.gov Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy | — | Completed | — | — | — |
NCT00414323CT.gov Evaluation of the Effects of Duloxetine on Norepinephrine | — | Completed | — | — | — |
NCT00384436CT.gov Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients | — | Completed | — | — | — |
NCT00464711CT.gov Brain GABA Levels and Treatment Response in Major Depressive Disorder | — | Completed | — | — | — |
NCT00367341CT.gov Imaging Predictors of Treatment Response in Depression | — | Completed | — | — | — |
NCT00404755CT.gov Dichotic Listening as a Predictor of Medication Response in Depression | — | Completed | — | — | — |
NCT00351169CT.gov Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT00351910CT.gov Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT01876823CT.gov Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment | — | Completed | — | — | — |
NCT00295347CT.gov Mineralocorticoid Receptor in the Treatment of Severe Depression | — | Completed | — | — | — |
NCT00296933CT.gov Memory Functioning and Antidepressant Treatment | — | Completed | — | — | — |
NCT00135421CT.gov Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00608543CT.gov Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression | — | Completed | — | — | — |
NCT01148472CT.gov Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00232700CT.gov Investigation of a Combination Treatment of Escitalopram and rTMS | — | Completed | — | — | — |
NCT00209807CT.gov Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder | — | Unknown | — | — | — |
NCT00107120CT.gov The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00108979CT.gov Study of Escitalopram in Adult Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00239954CT.gov Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder | — | Unknown | — | — | — |
NCT00220636CT.gov Abilify as an Adjunctive Treatment for Refractory Depression | — | Completed | — | — | — |
NCT00208169CT.gov Abilify Therapy for Reducing Comorbid Substance Abuse | — | Completed | — | — | — |
NCT00166296CT.gov Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients | — | Completed | — | — | — |
NCT00109044CT.gov Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00296712CT.gov Are Two Antidepressants a Good Initial Treatment for Depression? | — | Completed | — | — | — |
NCT00220480CT.gov A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression | — | Unknown | — | — | — |
NCT00229333CT.gov Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia | — | Unknown | — | — | — |
NCT00296777CT.gov Treatment of Depression Following Multiple Brain Tests | — | Completed | — | — | — |
NCT00149825CT.gov Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome | — | Completed | — | — | — |
NCT00086307CT.gov Lexapro and Pramipexole and to Treat Major Depression | — | Completed | — | — | — |
NCT00194948CT.gov Treatment Choices for Improving Adherence and Outcome | — | Completed | — | — | — |
NCT00222820CT.gov Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study | — | Completed | — | — | — |
NCT00166114CT.gov Depression, Epinephrine, and Platelet Function | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Escitalopram (this asset) | Shanghai 7th People's Hospital | Approved | BBB · 72 |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| VENLOR | Dr. Inge Winter | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Escitalopram
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 77 |
| Dysthymic Disorder | — | P4 | BBB · 76 |
| Bipolar Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Escitalopram in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/escitalopram-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →